Microcap biopharmaceutical researcher Adventrx Pharmaceuticals (ANX +11.2%) gets a pop today...

|By:, SA News Editor

Microcap biopharmaceutical researcher Adventrx Pharmaceuticals (ANX +11.2%) gets a pop today after announcing that it's initiated patient recruitment for its Phase 3 clinical study of ANX-188 in sickle cell disease. Santosh Vetticaden, the company's Chief Medical Officer, says the drug "has the potential to be the first FDA-approved product for sickle cell disease vaso-occlusive crisis in fifteen years."